Breaking
Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHDFDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast CancerRAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup
🌏 NMPA

Partnerships

Page 1 • 1 item

Discover global pharma partnerships driving innovation and market growth. Essential intelligence for BD, investors, and analysts.

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
AnalysisPainMay 2, 2026

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era

Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to resolve claims related to the opioid crisis. This landmark deal signifies a major turning point in the legal and societal reckoning with the epidemic.

Dr. Yuki Tanaka